Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - macrogol 3350 - powder for oral solution - 2.95 grams

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - macrogol 3350 - powder for oral solution - 5.9 grams

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - macrogol 3350 - powder for oral solution - 2.95 grams

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - macrogol 3350 - powder for oral solution - 5.9 grams

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - macrogol 3350 5.9 g;   - powder for oral solution - 5.9 g - active: macrogol 3350 5.9 g   excipient: acesulfame potassium aspartame lemon flavour durarome 501341 td0590 potassium chloride sodium bicarbonate sodium chloride sodium sulfate

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 15 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 15 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited  - siponimod fumaric acid - multiple sclerosis, relapsing-remitting - selective immunosuppressants - mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (spms) with active disease evidenced by relapses or imaging features of inflammatory activity.

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - letrozole - tablet, film coated - 2.5 mg - letrozole 2.5 mg